Global Approval of Xenpozyme Revolutionizes ASMD Treatment

New York, Friday, 21 November 2025.
The worldwide approval of Xenpozyme, an enzyme replacement therapy, is set to enhance Acid Sphingomyelinase Deficiency (ASMD) diagnosis and treatment, propelling market growth until 2035.